RLMD Jumped 85% on Phase 2 Data and $160M Financing — RTPR Had the Wire in 246ms
RLMD surged 85% on back-to-back press releases. RTPR delivered the wire in 246ms at $4.55 before the run to $8.45.
Relmada Therapeutics (NASDAQ: RLMD) surged 85% on March 9, 2026, after dropping two press releases in rapid succession. RTPR subscribers saw the first wire at $4.55 — the entry point before the stock ran to a peak of $8.45.
What Happened
Relmada issued back-to-back press releases that hit the wire moments apart. The first announced 12-month interim data from the company's Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer. The second announced an oversubscribed $160 million private placement financing.
The combination was significant. Clinical data alone can move biotech stocks, but pairing positive interim results with a substantial capital raise signals institutional confidence in the program's trajectory. The $160 million financing, described as oversubscribed, indicated demand exceeded the initial offering size.
Why It Moved
Biotech catalysts often come down to two questions: does the drug work, and can the company fund development? Relmada answered both in the same morning.
The Phase 2 interim data provided a clinical update on NDV-01, the company's bladder cancer candidate. While the full data details were in the release, the market's reaction suggested the 12-month results met or exceeded expectations.
The financing announcement removed near-term dilution uncertainty. An oversubscribed private placement at this stage typically means institutional investors are willing to pay for shares at negotiated terms, often interpreted as a vote of confidence in upcoming milestones.
The stock moved from $4.55 at the time of the wire to $8.45 at its peak — an 85% gain for those positioned early.
The Speed Advantage
RTPR Speed: 246ms delivery. RLMD was trading at $4.55 when RTPR subscribers received the wire. The stock peaked at $8.45. Free news aggregators and financial portals typically lag wire services by 2–4 minutes.
Back-to-back press releases compress the reaction window even further. By the time a second headline confirms the first, much of the move has already occurred. Having the first wire in 246ms — with RLMD still at $4.55 — gave subscribers the full picture before price discovery accelerated.
Context
Relmada Therapeutics focuses on CNS and oncology therapeutics. NDV-01 is part of the company's pipeline targeting bladder cancer, a space with significant unmet need in non-muscle invasive disease where recurrence rates remain high.
The simultaneous data release and financing is a pattern seen when biotech management teams want to capitalize on positive clinical momentum. It reduces the window for short sellers to act on the data release alone and locks in capital at favorable terms.
Want This Speed?
RTPR delivered this wire in 246ms at $4.55. By the time free sources showed the news, RLMD was already moving toward $8.45.
See what real-time wire access costs: rtpr.io/pricing
Read the API docs: rtpr.io/docs